Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis

Affiliations

• ¹ Department of Hematology, Juntendo University School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. komatsun@juntendo.ac.jp.
• ² Department of Hematology and Oncology, University of Yamanashi, Yamanashi, 409-3898, Japan.
• ³ Department of Gastroenterology and Hematology, University of Miyazaki, Miyazaki, 889-1692, Japan.
• ⁴ Department of Hematology, Kobe City Medical Center General Hospital, Kobe, 650-0047, Japan.
• ⁵ Blood Transfusion Service, Mie University, Tsu, Mie, 514-8507, Japan.
• ⁶ Department of Hematology, Tokyo Medical University, Tokyo, 160-8402, Japan.
• ⁷ Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, 010-8502, Japan.
• ⁸ Novartis Pharma KK, Tokyo, 105-6333, Japan.
• ⁹ Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, 812-8582, Japan.